BR112014017683A2 - controle glicêmico intensificado usando ad36e4orf1 e inibidor de akt1 - Google Patents

controle glicêmico intensificado usando ad36e4orf1 e inibidor de akt1

Info

Publication number
BR112014017683A2
BR112014017683A2 BR112014017683A BR112014017683A BR112014017683A2 BR 112014017683 A2 BR112014017683 A2 BR 112014017683A2 BR 112014017683 A BR112014017683 A BR 112014017683A BR 112014017683 A BR112014017683 A BR 112014017683A BR 112014017683 A2 BR112014017683 A2 BR 112014017683A2
Authority
BR
Brazil
Prior art keywords
glycemic control
ad36e4orf1
akt1 inhibitor
enhanced glycemic
akt1
Prior art date
Application number
BR112014017683A
Other languages
English (en)
Portuguese (pt)
Inventor
Dhurandhar Nikhil
Krishnapuram Rashmi
Original Assignee
Univ Louisiana State
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Louisiana State filed Critical Univ Louisiana State
Publication of BR112014017683A2 publication Critical patent/BR112014017683A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10333—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112014017683A 2012-01-20 2013-01-18 controle glicêmico intensificado usando ad36e4orf1 e inibidor de akt1 BR112014017683A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261588959P 2012-01-20 2012-01-20
PCT/US2013/022126 WO2013109876A1 (en) 2012-01-20 2013-01-18 Enhanced glycemic control using ad36e4orf1 and akt1 inhibitor

Publications (1)

Publication Number Publication Date
BR112014017683A2 true BR112014017683A2 (pt) 2017-06-27

Family

ID=47664431

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014017683A BR112014017683A2 (pt) 2012-01-20 2013-01-18 controle glicêmico intensificado usando ad36e4orf1 e inibidor de akt1

Country Status (7)

Country Link
US (1) US9433659B2 (enExample)
EP (1) EP2804616B1 (enExample)
JP (1) JP6175076B2 (enExample)
AU (1) AU2013209580B2 (enExample)
BR (1) BR112014017683A2 (enExample)
CA (1) CA2865202A1 (enExample)
WO (1) WO2013109876A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025080777A1 (en) * 2023-10-10 2025-04-17 Texas Tech University System Ad36e4orf1 peptide fragments as anti-diabetic agents
WO2025264791A1 (en) * 2024-06-18 2025-12-26 Texas Tech University System Recruiting the contribution of dlg1 to enhance insulin signaling pathway

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2472325T3 (es) * 2005-11-30 2014-06-30 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Gen y proteína del adenovirus 36 E4 orf 1 y sus usos
AR064010A1 (es) 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt

Also Published As

Publication number Publication date
US20150038412A1 (en) 2015-02-05
CA2865202A1 (en) 2013-07-25
AU2013209580A1 (en) 2014-08-07
EP2804616A1 (en) 2014-11-26
EP2804616B1 (en) 2018-07-18
US9433659B2 (en) 2016-09-06
AU2013209580B2 (en) 2017-11-30
HK1204449A1 (en) 2015-11-20
JP6175076B2 (ja) 2017-08-02
WO2013109876A1 (en) 2013-07-25
JP2015505535A (ja) 2015-02-23

Similar Documents

Publication Publication Date Title
NI201400078A (es) Derivados de lactamas útiles como inhibidores mutantes de idh1
LT2916860T (lt) Diabeto gydymui skirta kompozicija, apimanti oksintomodulino analogą
UY34165A (es) ?compuestos aldh-2 mitocondriales humanos para el tratamiento de la adicción?.
CR20140229A (es) Nuevos derivados bicíclicos de dihidroisoquinolin-1-ona
CO6761400A2 (es) Combinación de análogos de glucagón acilados con análogos de insulina
UY33958A (es) Inhibidores de la glucosilceramida sintasa
CL2015000177A1 (es) Composición para el tratamiento de la hiperlipidemia que comprende un derivado de oxintomodulina
CO6820281A1 (es) Cepillo de dientes que proporciona retroalimentación prácticamente instantanea
MX373664B (es) Metodos y composiciones para el control de malezas.
CL2015001486A1 (es) Composición que comprende agentes de control biológico.
BR112014004726A2 (pt) combinação farmacêutica para uso no controle glicêmico em pacientes de diabetes tipo 2
MX377067B (es) Métodos y composiciones para el control de malezas.
AR087956A1 (es) METODOS Y COMPOSICIONES QUE MODULAN ACETIL-CoA CARBOXILASA PARA EL CONTROL DE MALEZAS
MX2019009856A (es) Activadores de cinasa de piruvato para su uso en terapia.
BRPI1100666A2 (pt) Método para produzir um l-aminoácido
DK2741763T3 (da) Sammensætning til kontrolleret ovariestimulering.
MX374468B (es) Composicion farmaceutica acuosa semisolida que contiene tapentadol.
BR112014009889A2 (pt) compostos dissubstituídos, compostos e composição farmacêutica
BR112014014536A2 (pt) um inalador compreendendo uma composição contendo tiotrópio
BR112014009963A2 (pt) composição dietética
UY34575A (es) Composiciones y métodos para el tratamiento de diabetes y/u obesidad
BR112013027403A2 (pt) composições que compreendem uma antimetabólito de glicose e selênio
CO6920289A2 (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib.
BR112013018287A2 (pt) derivados monoterpenos de chalcona ou de diidrochalcona e sua utilização como agentes de despigmentação
BR112013020359B8 (pt) Colágeno gelificável e meios para a sua provisão

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2614 DE 09-02-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.